1. |
Daniel TM. The history of tuberculosis. Respir Med, 2006, 100(11): 1862-1870.
|
2. |
Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2019, 23(6): 645-662.
|
3. |
Khan I, Ahmad N, Khan S, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health, 2019, 12(6): 809-815.
|
4. |
Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One, 2009, 4(9): e6914.
|
5. |
Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis, 2009, 9(3): 153-161.
|
6. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
7. |
曾宪涛, 刘慧, 陈曦, 等. Meta 分析系列之四: 观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4): 297-299.
|
8. |
王丹, 翟俊霞, 牟振云, 等. Meta 分析中的异质性及其处理方法. 中国循证医学杂志, 2009, 9(10): 1115-1118.
|
9. |
Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One, 2013, 8(12): e82943.
|
10. |
Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine (Baltimore), 2020, 99(30): e21296.
|
11. |
Zhang Q, Wu Z, Zhang Z, et al. Efficacy and effect of free treatment on multidrug-resistant tuberculosis. Exp Ther Med, 2016, 11(3): 777-782.
|
12. |
Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis, 2017, 17(1): 573.
|
13. |
Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. Clin Microbiol Infect, 2018, 24(4): 381-388.
|
14. |
Yu MC, Chiang CY, Lee JJ, et al. Treatment outcomes of multidrug-resistant tuberculosis in taiwan: tackling loss to follow-up. Clin Infect Dis, 2018, 67(2): 202-210.
|
15. |
王丹吉, 卢鹏, 刘巧, 等. 耐多药肺结核患者治疗转归的影响因素分析. 结核病与肺部健康杂志, 2017, 6(3): 254-259.
|
16. |
张玲. 耐多药肺结核治疗及其影响因素分析. 临床肺科杂志, 2016, 21(8): 1508-1511.
|
17. |
吕德良, 谭卫国, 张乐平, 等. 影响深圳市耐多药结核病患者治愈的相关因素的双向性队列研究. 临床肺科杂志, 2017, 22(7): 1165-1168.
|
18. |
丁晓艳, 刘巧, 孔雯, 等. 2009-2013 年江苏省耐多药患者治疗转归及影响因素分析. 结核病与肺部健康杂志, 2016, (4): 271-276.
|
19. |
周正华, 梁志勇, 邓小懂. 清远市耐多药肺结核患者治疗效果及其影响因素分析. 吉林医学, 2020, 41(3): 648-650.
|
20. |
Collaborative group for the meta-analysis of individual patient data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150): 821-834.
|
21. |
沈胜伟. DOT 管理模式在肺结核疾病控制中的应用. 中医药管理杂志, 2014, 22(2): 244-245.
|
22. |
Park SK, Lee WC, Lee DH, et al. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis, 2004, 8(3): 361-368.
|
23. |
屠德华. 肺结核化学治疗中标准化方案与个体化方案的应用. 中华结核和呼吸杂志, 2004, 27(2): 75-76.
|
24. |
杜建, 徐彩红, 李琦, 等. 不同类型治疗方案治疗耐多药结核病效果文献分析. 中国防痨杂志, 2010, 32(8): 421-426.
|
25. |
李春华, 赵攀, 吕圣秀, 等. 127 例耐多药肺结核 CT 影像学改变与临床. 重庆医学, 2014, (23): 3078-3080.
|
26. |
Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet, 2008, 372(9647): 1403-1409.
|
27. |
Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet, 2010, 375(9728): 1798-1807.
|
28. |
吴兰香. 耐多药结核病人影响因素病例对照研究. 中国公共卫生, 2011, 27(4): 401-402.
|
29. |
郭红革, 陈伟, 赵文钧. 珠海市 2015-2017 年结核病耐药状况分析. 华南预防医学, 2018, 44(3): 258-260.
|